Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage (msm)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01836757
Recruitment Status : Unknown
Verified April 2013 by Thomas Pagonis, G.Papanikolaou Research Group.
Recruitment status was:  Recruiting
First Posted : April 22, 2013
Last Update Posted : April 22, 2013
Sponsor:
Information provided by (Responsible Party):
Thomas Pagonis, G.Papanikolaou Research Group

Brief Summary:
To delineate the effect of MSM on osteoarthritis

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: MethylSulfonylMethane (MSM) Drug: Placebo Phase 1

Detailed Description:
Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte
Study Start Date : September 2012
Estimated Primary Completion Date : September 2013
Estimated Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: MSM group
Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
Drug: MethylSulfonylMethane (MSM)
Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)

Placebo Comparator: Placebo Group
Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
Drug: Placebo



Primary Outcome Measures :
  1. Number of participants with improved Mobility [ Time Frame: 26 weeks ]
    Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)


Secondary Outcome Measures :
  1. Pain Scores on the Visual Analog Scale [ Time Frame: 26 weeks ]
    On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Knee and hip OA
  • men and women >45 years of age

Exclusion Criteria:

  • any other type of arthritis
  • chronic pain syndrome
  • arthroscopic surgery in the past 8 months
  • intra-articular corticosteroidsin the past 8 months
  • hyaluronic acid injections in the past 8 months
  • narcotic pain killers use
  • renal or hepatic disease
  • body mass index (BMI) >45 kg/m2
  • cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01836757


Contacts
Layout table for location contacts
Contact: Thomas Pagonis, MD, PhD 00306980488686 iatros1@yahoo.com

Locations
Layout table for location information
Greece
G. Papanikolaou Hospital Recruiting
Thessaloniki, Greece, 57010
Contact: Panagiotis Givisis, MD, PhD    00306945264010      
Principal Investigator: Thomas Pagonis, MD, PhD         
Sponsors and Collaborators
G.Papanikolaou Research Group
Investigators
Layout table for investigator information
Principal Investigator: Thomas Pagonis, MD, PhD Aristotle's University of Thessaloniki

Layout table for additonal information
Responsible Party: Thomas Pagonis, Orthopaedic Surgeon, G.Papanikolaou Research Group
ClinicalTrials.gov Identifier: NCT01836757    
Other Study ID Numbers: msm2012
First Posted: April 22, 2013    Key Record Dates
Last Update Posted: April 22, 2013
Last Verified: April 2013
Keywords provided by Thomas Pagonis, G.Papanikolaou Research Group:
osteoarthritis
CAM treatments
MSM
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Dimethyl sulfone
Anti-Inflammatory Agents